Letermovir
| 證據等級: L5 | 預測適應症: 10 個 |
目錄
Letermovir: From CMV Prophylaxis to Vulvovaginal Candidiasis
One-Sentence Summary
Letermovir is a first-in-class CMV DNA terminase complex inhibitor established for preventing cytomegalovirus (CMV) infection in haematopoietic stem cell transplant (HSCT) recipients. The TxGNN model predicts it may be effective for Vulvovaginal Candidiasis with a score of 99.88%, however no clinical trials or supporting literature exist for this direction. This prediction is very likely a model artefact — Letermovir targets a viral enzyme entirely absent in fungi — and the current recommendation is to Hold.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | CMV prophylaxis in HSCT recipients (established use; no EU authorization record found in dataset) |
| Predicted New Indication | Vulvovaginal Candidiasis |
| TxGNN Prediction Score | 99.88% |
| Evidence Level | L5 |
| EU Market Status | ✗ Not Marketed (0 authorizations in dataset) |
| Number of Authorizations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not formally available in the Evidence Pack. Based on established scientific knowledge, Letermovir (brand name Prevymis) belongs to a novel class of antivirals that selectively inhibits the CMV DNA terminase complex — a three-subunit viral enzyme (UL56 / UL89 / UL51) responsible for cleaving and packaging viral DNA into newly assembled capsids. This mechanism of action is entirely specific to the Herpesviridae family and has no structural or functional counterpart in any fungal pathogen.
Vulvovaginal candidiasis is caused by Candida spp. (predominantly C. albicans), which are eukaryotic fungi. All clinically effective antifungal drug classes act through targets unrelated to DNA terminase: azoles disrupt ergosterol biosynthesis, polyenes form pores in the fungal cell membrane, and echinocandins inhibit β-(1,3)-glucan synthase in the cell wall. None of these mechanisms overlap with CMV DNA packaging, and Candida spp. do not encode any homologue of the herpesvirus terminase complex.
The TxGNN model’s very high prediction score (99.88%) almost certainly reflects spurious signal propagation between “viral infectious disease” and “fungal infectious disease” node clusters in the underlying knowledge graph — both belong to the same broad infection category neighbourhood — rather than any biologically plausible cross-indication mechanism. This prediction should be regarded as a false positive, and no further investigation is warranted for this specific indication.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
EU Market Information
No EU authorization records are present in the current dataset (0 authorizations recorded). This appears to be a data pipeline gap: Letermovir (Prevymis) is externally documented as EMA-approved for CMV prophylaxis in adult CMV-seropositive HSCT recipients. Please verify current authorization status and SmPC directly via the EMA product database.
Safety Considerations
Please refer to the SmPC for safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: Vulvovaginal candidiasis is a fungal disease, and Letermovir’s pharmacological target — the CMV DNA terminase complex — is a viral enzyme with no equivalent in fungi. There is zero mechanistic, preclinical, or clinical evidence to support antifungal activity, and the TxGNN high score is consistent with a graph-neighbourhood artefact rather than a real biological signal.
To proceed, the following is needed:
- No further investigation of this specific indication is recommended.
- Resources should be redirected to the higher-priority repurposing hypotheses identified within the same prediction set:
- AIDS / HIV co-infection (Rank 7 — L3, “Research Question”): A completed open-label randomised pilot study (NCT05362916, N=33) assessed Letermovir’s effect on gut inflammation in ART-treated, CMV-seropositive people living with HIV; reviewing its published results (linked to PMID 36690406) should be the immediate next step. A second terminated Phase 2 RCT (NCT04840199, N=44) warrants investigation of the termination reason before this direction is advanced further.
- Varicella Zoster Infection (Rank 10 — L4, “Research Question”): A 2024 mutagenesis study (PMID 38517165) directly characterises Letermovir’s interaction with the VZV portal protein, providing an early mechanistic hypothesis for cross-herpesvirus activity. In vitro VZV activity confirmation is the critical next step before any clinical study is considered.
- Fungal Infectious Disease via indirect immune pathway (Rank 2 — L4, Hold): PMID 41371495 (2026 cohort) directly examines whether Letermovir prophylaxis reduces invasive fungal infections in HSCT patients through CMV-mediated immune suppression. Reviewing this result is warranted before finalising a blanket “Hold” on any CMV–fungal infection relationship.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.